Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Cambrex Corp (CBM) NYSE

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]] [[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]] [[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
3-Month Performance
View Chart

Fundamentals

See More
  • Market Capitalization, $K 1,795,580
  • Shares Outstanding, K 32,150
  • Annual Sales, $ 433,330 K
  • Annual Income, $ 57,220 K
  • 36-Month Beta 1.95
  • Price/Sales 3.83
  • Price/Book 4.89

Price Performance

See More
Period Period Low Period High Performance
1-Month
52.25 +3.16%
on 12/21/16
57.40 -6.10%
on 01/09/17
+0.70 (+1.32%)
since 12/19/16
3-Month
38.30 +40.73%
on 11/03/16
57.40 -6.10%
on 01/09/17
+12.60 (+30.51%)
since 10/19/16
52-Week
29.50 +82.71%
on 02/08/16
59.41 -9.27%
on 07/21/16
+14.03 (+35.19%)
since 01/19/16

Most Recent Stories

More News
Merck KGaA Expands Distribution Deal with Roche (revised)

Germany-based Merck KGaA announced that it has expanded the distribution alliance with Roche Holding AG (RHHBY).

Merck KGaA Expands Distribution Deal with Roche (revised)

Germany-based Merck KGaA announced that it has expanded the distribution alliance with Roche Holding AG (RHHBY).

Momenta (MNTA) to Receive $50M Under CSL Collaboration

Momenta Pharmaceuticals, Inc. (MNTA) entered into an exclusive research collaboration and worldwide license agreement with CSL Limited.

Roche's (RHHBY) Lucentis Gets FDA Nod for Fifth Indication

Roche Holding AG (RHHBY) announced today that the FDA has approved a label expansion of ophthalmology drug Lucentis- fifth indication.

Zacks.com featured highlights: Braskem, Cambrex, Daqo New Energy, State National Companies and International Consolidated Airlines Group

Zacks.com featured highlights: Braskem, Cambrex, Daqo New Energy, State National Companies and International Consolidated Airlines Group

Genocea Stock Up on Positive Genital Herpes Infections Data

Genocea Biosciences, Inc. (GNCA) announced encouraging six-month data from a planned interim analysis of its ongoing placebo-controlled phase IIb study on GEN-003 for the treatment of genital herpes infections....

Biogen Licenses Amunix's XTEN Technology for Factor IX Drug

Biogen Inc. (BIIB) exercised its option to enter into an exclusive, global license agreement with Amunix Operating Inc. to incorporate the latter's proprietary XTEN half-life extension technology in developing...

Ultragenyx's (RARE) KRN23 Accepted for Review in the EU

Ultragenyx (RARE) announced that EMA has accepted to review its MAA for KRN23 for the treatment of X-linked hypophosphatemia.

Amgen's Repatha Wins Over Sanofi & Regeneron's Praluent

The U.S. District Court in Delaware granted Amgen, Inc. (AMGN) permanent injunction against infringement by Sanofi and Regeneron of two patents owned by the former for Repatha.

Arena, Eisai Modify Marketing & Supply Agreement for Belviq

Arena Pharmaceuticals, Inc. (ARNA) announced that it has amended the marketing and supply agreement with Eisai Co., Ltd. (ESALY) for Belviq.

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Buy with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak. Long term indicators fully support a continuation of the trend.

See More

Business Summary

Cambrex Corporation manufactures and markets a broad line of specialty chemicals and commodity chemical intermediates and also manufactures chemicals to customer specifications. There are five product categories: pharmaceutical bulk actives; pharmaceutical intermediates; organic intermediates; performance...

See More

Support & Resistance

2nd Resistance Point 55.22
1st Resistance Point 54.98
Last Price 53.85
1st Support Level 54.28
2nd Support Level 53.82

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.